lifestyle.longislandreport.org

Author: Tempest Therapeutics

Tempest Reports Year End 2025 Financial Results and Provides Business Update

March 30, 2026
Tempest Therapeutics Announces Up To $6 Million Private Placement

March 23, 2026
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

March 11, 2026
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

February 25, 2026
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

February 13, 2026
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

February 10, 2026
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

January 20, 2026